The expiration of the Ozempic patent will lead to a significant decrease in prices as generic versions from Indian pharmaceutical companies enter the market, but Argentine copies remain notably expensive.
The expiration of the Ozempic and Wegovy patents has paved the way for Indian pharmaceutical companies to introduce generic versions of these popular diabetes and weight-loss medications. This change is expected to dramatically lower the prices of these treatments in markets where they become available. Among the companies preparing to launch their products, Natco Pharma plans to offer a version of semaglutide at a significantly lower monthly price compared to current Argentine options.
